Franco Vigile (@francovigile) 's Twitter Profile
Franco Vigile

@francovigile

Entrepreneur with a passion for creating companies that’ll improve one’s quality of life. Founder @HALUGENSCI | Co-Founder & CEO @nzymebio

ID: 897581191741747201

calendar_today15-08-2017 22:10:07

3,3K Tweet

827 Followers

258 Following

Franco Vigile (@francovigile) 's Twitter Profile Photo

Grateful to be working towards creating safe, effective and efficient treatments for LPR, addressing a significant unmet clinical need.

Franco Vigile (@francovigile) 's Twitter Profile Photo

I’d like to congratulate my co-founder and friend on this honourable achievement. I believe this prestigious award is a testament to her groundbreaking work. Dr. Johnston’s research is poised to make critical therapeutic impacts in the area of reflux and related diseases.

N-Zyme Biomedical Inc. (@nzymebio) 's Twitter Profile Photo

N-Zyme would like to congratulate Simon Blaine-Sauer and team on their recent paper ‘The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes’ that was just published in the

N-Zyme Biomedical Inc. (@nzymebio) 's Twitter Profile Photo

N-Zyme is pleased to announce that its co-founders, Dr. Nikki Johnston and Franco Vigile, filed a patent on March 27th, 2024, for ‘Methods and compositions for treatment of peptic ulcers and/or peptic ulcer disease’ (Provisional application # 63/569,875). This patent filing

N-Zyme is pleased to announce that its co-founders, Dr. Nikki Johnston and Franco Vigile, filed a patent on March 27th, 2024, for ‘Methods and compositions for treatment of peptic ulcers and/or peptic ulcer disease’ (Provisional application # 63/569,875). This patent filing
Franco Vigile (@francovigile) 's Twitter Profile Photo

Modern diagnostic technologies have revealed why a significant percentage of people experience little to no relief with currently available treatment options for reflux and our mission is to address this critical unmet need in clinical care.

N-Zyme Biomedical Inc. (@nzymebio) 's Twitter Profile Photo

An excellent discussion with N-Zyme’s co-founder and Chief Scientific Officer, Dr. Nikki Johnston on the impact of LPR and GERD on millions of individuals and the groundbreaking, transformative efforts we are undertaking at N-Zyme to meet this significantly unmet clinical need.

An excellent discussion with N-Zyme’s co-founder and Chief Scientific Officer, Dr. Nikki Johnston on the impact of LPR and GERD on millions of individuals and the groundbreaking, transformative efforts we are undertaking at N-Zyme to meet this significantly unmet clinical need.
Franco Vigile (@francovigile) 's Twitter Profile Photo

Welcome to the team, Brendan Hussey, Ph.D! We’re looking forward to continuing to work together to revolutionize the reflux industry and address a significantly unmet clinical need.

N-Zyme Biomedical Inc. (@nzymebio) 's Twitter Profile Photo

N-Zyme is pleased to announce that, in addition to its transition to a Delaware corporation earlier this year, the Company has established a new corporate headquarters located at 1225 Discovery Parkway, Suite 260E, Wauwatosa, WI 53266.

N-Zyme is pleased to announce that, in addition to its transition to a Delaware corporation earlier this year, the Company has established a new corporate headquarters located at 1225 Discovery Parkway, Suite 260E, Wauwatosa, WI 53266.